Literature DB >> 2578283

Heterogeneity of colorectal adenocarcinomas evaluated by flow cytometry and histopathology.

P Quirke, J E Dyson, M F Dixon, C C Bird, C A Joslin.   

Abstract

Flow cytometry and histopathology were utilised in evaluating 50 primary and 16 metastatic colorectal carcinomas to determine the influence of heterogeneity and proportion of dying cells on pathological assessments. A new procedure was developed for staining unfixed whole cells with acridine orange and ethidium bromide to quantify DNA and RNA content and number of dead and dying cells. Attempts were made to reduce interobserver variation in histological assessment and to determine whether flow cytometry could refine current grading and staging procedures. Interobserver variation in grading was not improved by estimating proportions of differing grades in multiple samples from individual tumours. Considerable heterogeneity was observed within tumours although this was less apparent when defining ploidy status than histological grade. No consistent differences were observed between superficial and deep parts of tumours or between primary and secondary tumours by either method of analysis. The proportion of dead and dying cells varied widely between tumours but there was no correlation with tumour grade or stage. Non-diploid tumours were not of more advanced stage or poorer histological grade than diploid tumours. Since ploidy status may be an important prognostic factor, analysis of colorectal carcinomas by flow cytometry could be of greater value than conventional grading and staging procedures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578283      PMCID: PMC1976809          DOI: 10.1038/bjc.1985.14

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Cell death in normal and malignant tissues.

Authors:  E H Cooper; A J Bedford; T E Kenny
Journal:  Adv Cancer Res       Date:  1975       Impact factor: 6.242

2.  Is histologic grading of colon carcinoma a valid procedure?

Authors:  R E QUALHEIM; E A GALL
Journal:  AMA Arch Pathol       Date:  1953-11

3.  THE GRADING AND PROGNOSIS OF CARCINOMA OF THE COLON AND RECTUM.

Authors:  R S Grinnell
Journal:  Ann Surg       Date:  1939-04       Impact factor: 12.969

4.  Cell proliferation kinetics in five human solid tumors.

Authors:  E Frindel; E Malaise; M Tubiana
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

5.  Cell loss in malignant tumours in man.

Authors:  S B Refsum; P Berdal
Journal:  Eur J Cancer       Date:  1967-08       Impact factor: 9.162

6.  The limitations of preoperative grading of rectal carcinoma.

Authors:  P H Chapuis; R C Newland; O F Dent; R Jaworski; D Watson; M T Pheils
Journal:  J Surg Oncol       Date:  1982-08       Impact factor: 3.454

7.  A reappraisal of staging and therapy for patients with cancer of the rectum. I. Development of two new systems of staging.

Authors:  A R Feinstein; C R Schimpff; E W Hull
Journal:  Arch Intern Med       Date:  1975-11

8.  Observer variation in the histological grading of rectal carcinoma.

Authors:  G D Thomas; M F Dixon; N C Smeeton; N S Williams
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

9.  Relationship between cell ploidy and glucocorticoid induced death in human lymphoid cell lines.

Authors:  J E Dyson; P Quirke; C C Bird; J B McLaughlin; C R Surrey
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

10.  Large-bowel carcinomas with different ploidy, related to secretory component, IgA, and CEA in epithelium and plasma.

Authors:  T O Rognum; E Thorud; K Elgjo; P Brandtzaeg; H Orjasaeter; K Nygaard
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

View more
  21 in total

1.  Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer.

Authors:  S Rowley; K M Newbold; J Gearty; M R Keighley; I A Donovan; J P Neoptolemos
Journal:  World J Surg       Date:  1990 Jul-Aug       Impact factor: 3.352

2.  Tumor DNA content in resectable, primary colorectal carcinoma.

Authors:  W A Kokal; R L Gardine; K Sheibani; P L Morris; E Prager; I W Zak; J J Terz
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

3.  Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis.

Authors:  H S Goh; J R Jass; W S Atkin; J Cuzick; J M Northover
Journal:  Int J Colorectal Dis       Date:  1987-02       Impact factor: 2.571

Review 4.  Reporting colorectal cancer.

Authors:  J R Jass; B C Morson
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

Review 5.  The prognostic value of flow cytometric DNA analysis in colorectal cancer patients.

Authors:  H Suzuki
Journal:  Jpn J Surg       Date:  1988-09

6.  Detection of ploidy in colorectal tumors. A comparison between flow cytometry and cytogenetics.

Authors:  A Laquerriere; P Peulve; M A Scotte; S X Ma; M Paresy; P Teniere; J Hemet
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

7.  Clinical importance of DNA content in rectal cancer measured by flow cytometry.

Authors:  J R Jass; K Mukawa; H S Goh; S B Love; D Capellaro
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

8.  The clinical significance of regional variations in histologic differentiation within carcinomas of the colorectum.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; K Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  The prognostic role of the DNA ploidy pattern in colorectal cancer analysis using paraffin-embedded tissue by an improved method.

Authors:  Y Yamazoe; S Maetani; T Nishikawa; H Onodera; T Tobe; M Imamura
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

10.  Heterogeneity in ploidy and S-phase fraction in colorectal adenocarcinomas.

Authors:  G Lindmark; B Glimelius; L Påhlman; P Enblad
Journal:  Int J Colorectal Dis       Date:  1991-05       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.